PEComa Working Group
Advancing collaborative research in perivascular epithelioid cell tumors (PEComas).
Our Focus
Perivascular epithelioid cell tumors (PEComas) are ultra-rare mesenchymal tumors defined by their unique morphology and dual immunoreactivity for melanocytic and smooth muscle markers. Their molecular profile, most notably involving TSC1 and TSC2 mutations, provides an opportunity to explore targeted treatments, mechanisms of resistance, and tumor evolution under selective pressure.
The PEComa Working Group was established to integrate clinical, pathological, and molecular data across institutions, harmonize diagnostic and therapeutic approaches, and build collaborative studies within the PUSH network. By aligning expertise globally, the group seeks to improve understanding of PEComa biology and translate that knowledge into better outcomes for patients.
Our Objectives
The PEComa Working Group aims to conduct both retrospective and prospective studies, unify diagnostic and treatment frameworks, and establish the foundation for interventional research across the PUSH network.
Our Core Initiatives
The PEComa Working Group was established to integrate clinical, pathological, and molecular data across institutions, harmonize diagnostic and therapeutic approaches, and build collaborative studies within the PUSH network. By aligning expertise globally, the group seeks to improve understanding of PEComa biology and translate that knowledge into better outcomes for patients.
Our Objectives
The PEComa Working Group aims to conduct both retrospective and prospective studies, unify diagnostic and treatment frameworks, and establish the foundation for interventional research across the PUSH network.
Our Core Initiatives
- Launch an international PEComa registry within the PUSH network
- Conduct a retrospective study to define real-world outcomes.
- Correlate molecular alterations with treatment response and prognosis.
PEComa Group Team
Roberta Sanfilippo, MD, Chair
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrew Wagner, MD, Co-Chair
Dana-Farber Cancer Institute, Boston, USA
Chiara Fabbroni, MD, Member
Medical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Napolitano, MD, Member
Medical Oncologist, The Royal Marsden Hospital, London, United Kingdom
Paul Huang, PhD, Member
Group Leader, Molecular and Systems Oncology Laboratory, The Royal Marsden Hospital, London, United Kingdom
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrew Wagner, MD, Co-Chair
Dana-Farber Cancer Institute, Boston, USA
Chiara Fabbroni, MD, Member
Medical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Napolitano, MD, Member
Medical Oncologist, The Royal Marsden Hospital, London, United Kingdom
Paul Huang, PhD, Member
Group Leader, Molecular and Systems Oncology Laboratory, The Royal Marsden Hospital, London, United Kingdom
Join us in advancing international collaboration and improving clinical understanding of PEComa.
Join our mailing list
Stay connected with PUSH
Be informed about new working groups, research milestones, and opportunities to get involved